Reuters logo
in 6 months
BRIEF-Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 for Diabetic Macular Edema
January 10, 2017 / 7:46 AM / in 6 months

BRIEF-Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 for Diabetic Macular Edema

1 Min Read

Jan 10 (Reuters) - Thrombogenics Nv :

* Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 (Anti-PLGF) for Diabetic Macular Edema (DME)

* First results from study are expected in Q1 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below